Pelthos Therapeutics Financials - Benzinga

Pelthos Therapeutics Inc

PTHSAMEX

Trade with Public

Trade with Public

$22.65

-0.77-3.29%

Last update: Sep 10, 10:51 AM

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Stock Report

Pelthos Therapeutics Financials

Pelthos Therapeutics (PTHS) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Pelthos Therapeutics Q2 EPS $(6.62) Misses $(3.05) Estimate, Sales $15.603M Beat $15.273M Estimate

Pelthos Therapeutics (AMEX:PTHS) reported quarterly losses of $(6.62) per share which missed the analyst consensus estimate of $(3.05) by 117.05 percent. This is a 23.05 percent decrease over losses of $(5.38) per share

Benzinga Newsdesk

Earnings Scheduled For May 14, 2026

Benzinga Insights

PRO
Pelthos Therapeutics Q1 EPS $(3.09) Beats $(3.81) Estimate, Sales $10.906M Beat $10.445M Estimate

Pelthos Therapeutics (AMEX:PTHS) reported quarterly losses of $(3.09) per share which beat the analyst consensus estimate of $(3.81) by 18.9 percent. The company reported quarterly sales of $10.906 million which beat

Benzinga Newsdesk

Earnings Scheduled For March 19, 2026

Benzinga Insights

PRO
Pelthos Therapeutics Q4 EPS $(6.87) Misses $(4.13) Estimate, Sales $9.389M Beat $9.090M Estimate

Pelthos Therapeutics (AMEX:PTHS) reported quarterly losses of $(6.87) per share which missed the analyst consensus estimate of $(4.13) by 66.34 percent. This is a 115.36 percent decrease over losses of $(3.19) per share

Benzinga Newsdesk

PRO
Pelthos Therapeutics Q3 EPS $(5.30) Misses $(0.55) Estimate, Sales $7.406M Beat $4.380M Estimate

Pelthos Therapeutics (AMEX:PTHS) reported quarterly losses of $(5.30) per share which missed the analyst consensus estimate of $(0.55) by 863.64 percent. The company reported quarterly sales of $7.406 million which beat

Benzinga Newsdesk